The impact on toxicity and QOL of the one-day type transdermal fentanyl in patients who previously received oral oxycodone.

The impact on toxicity and QOL of the one-day type transdermal fentanyl in patients who previously received oral oxycodone. - The impact on toxicity and QOL of the one-day type transdermal fentanyl in patients who previously received oral oxycodone.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006485

Enrollment

Registered

2011-12-01

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer pain

Interventions

oral oxycodone-transdermal fentanyl

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Cancer pain 2. Receiving oral oxycodone 3. oxycodone dose is > 140mg/day and stable for over 1 week 4. age: = or > 20 5. written informed consent

Exclusion criteria

Exclusion criteria: 1. severe comorbidity 2. pregnant or lactating woman 3. disturbance of consciousness 4. contraindication to fentanyl 5. receiving narcotic antagonist analgesic 6. psychiatry disease

Design outcomes

Primary

Measure	Time frame
The improvement of toxicity and QOL	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026